Is PSTV or HYPR more profitable?

Hyperfine has a net margin of -226.88% compared to Plus Therapeutics' net margin of -230.24%. Hyperfine's return on equity of -98.83% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Plus Therapeutics -230.24% -198.48% -73.13% Hyperfine -226.88% -98.83% -67.09%

Does the media favor PSTV or HYPR?

In the previous week, Plus Therapeutics had 3 more articles in the media than Hyperfine. MarketBeat recorded 5 mentions for Plus Therapeutics and 2 mentions for Hyperfine. Hyperfine's average media sentiment score of 0.42 beat Plus Therapeutics' score of 0.40 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PSTV or CVRX more profitable?

CVRx has a net margin of -89.14% compared to Plus Therapeutics' net margin of -230.24%. CVRx's return on equity of -120.76% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Plus Therapeutics -230.24% -198.48% -73.13% CVRx -89.14% -120.76% -48.38%

Does the media favor PSTV or CVRX?

In the previous week, Plus Therapeutics had 3 more articles in the media than CVRx. MarketBeat recorded 5 mentions for Plus Therapeutics and 2 mentions for CVRx. Plus Therapeutics' average media sentiment score of 0.40 beat CVRx's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CVRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PSTV or MBOT?

In the previous week, Plus Therapeutics had 4 more articles in the media than Microbot Medical. MarketBeat recorded 5 mentions for Plus Therapeutics and 1 mentions for Microbot Medical. Plus Therapeutics' average media sentiment score of 0.40 beat Microbot Medical's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Microbot Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PSTV or NNOX?

In the previous week, Plus Therapeutics had 4 more articles in the media than Nano-X Imaging. MarketBeat recorded 5 mentions for Plus Therapeutics and 1 mentions for Nano-X Imaging. Plus Therapeutics' average media sentiment score of 0.40 beat Nano-X Imaging's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nano-X Imaging 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Plus Therapeutics (PSTV) Competitors

$5.53 +0.12 (+2.22%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$5.48 -0.06 (-0.99%)

As of 07:21 AM Eastern

Compare

PSTV vs. HYPR, CVRX, SNWV, MBOT, and NNOX

Should you buy Plus Therapeutics stock or one of its competitors? MarketBeat compares Plus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Plus Therapeutics include Hyperfine (HYPR), CVRx (CVRX), Sanuwave Health (SNWV), Microbot Medical (MBOT), and Nano-X Imaging (NNOX). These companies are all part of the "medical equipment" industry.

How does Plus Therapeutics compare to Hyperfine?

Plus Therapeutics (NASDAQ:PSTV) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Plus Therapeutics currently has a consensus target price of $56.40, indicating a potential upside of 919.89%. Hyperfine has a consensus target price of $1.78, indicating a potential upside of 26.48%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Plus Therapeutics had 3 more articles in the media than Hyperfine. MarketBeat recorded 5 mentions for Plus Therapeutics and 2 mentions for Hyperfine. Hyperfine's average media sentiment score of 0.42 beat Plus Therapeutics' score of 0.40 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperfine has a net margin of -226.88% compared to Plus Therapeutics' net margin of -230.24%. Hyperfine's return on equity of -98.83% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Hyperfine	-226.88%	-98.83%	-67.09%

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by insiders. Comparatively, 26.3% of Hyperfine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Plus Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Plus Therapeutics has higher earnings, but lower revenue than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	7.30	-$22.39M	-$2.30	N/A
Hyperfine	$15.33M	9.13	-$35.57M	-$0.41	N/A

Summary

Hyperfine beats Plus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Plus Therapeutics compare to CVRx?

Plus Therapeutics (NASDAQ:PSTV) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Plus Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, CVRx has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Plus Therapeutics has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	7.30	-$22.39M	-$2.30	N/A
CVRx	$59.07M	2.43	-$53.31M	-$2.02	N/A

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 13.9% of CVRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Plus Therapeutics had 3 more articles in the media than CVRx. MarketBeat recorded 5 mentions for Plus Therapeutics and 2 mentions for CVRx. Plus Therapeutics' average media sentiment score of 0.40 beat CVRx's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CVRx has a net margin of -89.14% compared to Plus Therapeutics' net margin of -230.24%. CVRx's return on equity of -120.76% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
CVRx	-89.14%	-120.76%	-48.38%

Plus Therapeutics presently has a consensus target price of $56.40, indicating a potential upside of 919.89%. CVRx has a consensus target price of $11.50, indicating a potential upside of 112.96%. Given Plus Therapeutics' higher probable upside, equities analysts clearly believe Plus Therapeutics is more favorable than CVRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

CVRx beats Plus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Plus Therapeutics compare to Sanuwave Health?

Sanuwave Health (NASDAQ:SNWV) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Sanuwave Health has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Sanuwave Health has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanuwave Health	$44.34M	2.82	$11.81M	$0.33	44.09
Plus Therapeutics	$5.21M	7.30	-$22.39M	-$2.30	N/A

Sanuwave Health currently has a consensus price target of $51.00, suggesting a potential upside of 250.52%. Plus Therapeutics has a consensus price target of $56.40, suggesting a potential upside of 919.89%. Given Plus Therapeutics' higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Sanuwave Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Plus Therapeutics had 5 more articles in the media than Sanuwave Health. MarketBeat recorded 5 mentions for Plus Therapeutics and 0 mentions for Sanuwave Health. Plus Therapeutics' average media sentiment score of 0.40 beat Sanuwave Health's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanuwave Health	Neutral
Plus Therapeutics	Neutral

42.5% of Sanuwave Health shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 14.4% of Sanuwave Health shares are owned by insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sanuwave Health has a net margin of 35.96% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanuwave Health	35.96%	-450.56%	44.87%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Summary

Sanuwave Health beats Plus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Plus Therapeutics compare to Microbot Medical?

Plus Therapeutics (NASDAQ:PSTV) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Microbot Medical has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Microbot Medical's return on equity of -21.84% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Microbot Medical	N/A	-21.84%	-20.71%

Plus Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 4.7% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Plus Therapeutics currently has a consensus target price of $56.40, suggesting a potential upside of 919.89%. Microbot Medical has a consensus target price of $6.63, suggesting a potential upside of 264.01%. Given Plus Therapeutics' higher probable upside, equities research analysts plainly believe Plus Therapeutics is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Microbot Medical has lower revenue, but higher earnings than Plus Therapeutics. Microbot Medical is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	7.30	-$22.39M	-$2.30	N/A
Microbot Medical	$105K	1,164.19	-$13.14M	-$0.26	N/A

In the previous week, Plus Therapeutics had 4 more articles in the media than Microbot Medical. MarketBeat recorded 5 mentions for Plus Therapeutics and 1 mentions for Microbot Medical. Plus Therapeutics' average media sentiment score of 0.40 beat Microbot Medical's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Microbot Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Microbot Medical beats Plus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Plus Therapeutics compare to Nano-X Imaging?

Plus Therapeutics (NASDAQ:PSTV) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Plus Therapeutics had 4 more articles in the media than Nano-X Imaging. MarketBeat recorded 5 mentions for Plus Therapeutics and 1 mentions for Nano-X Imaging. Plus Therapeutics' average media sentiment score of 0.40 beat Nano-X Imaging's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nano-X Imaging	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Plus Therapeutics has a net margin of -230.24% compared to Nano-X Imaging's net margin of -790.87%. Nano-X Imaging's return on equity of -64.65% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Nano-X Imaging	-790.87%	-64.65%	-57.27%

Plus Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Plus Therapeutics has higher earnings, but lower revenue than Nano-X Imaging. Plus Therapeutics is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	7.30	-$22.39M	-$2.30	N/A
Nano-X Imaging	$13.02M	9.73	-$75.02M	-$1.59	N/A

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Plus Therapeutics presently has a consensus price target of $56.40, indicating a potential upside of 919.89%. Nano-X Imaging has a consensus price target of $5.00, indicating a potential upside of 174.73%. Given Plus Therapeutics' higher possible upside, research analysts clearly believe Plus Therapeutics is more favorable than Nano-X Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Nano-X Imaging	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	3 Strong Buy rating(s)	2.83

Summary

Nano-X Imaging beats Plus Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Plus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSTV vs. The Competition

Export

Metric	Plus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.24M	$2.96B	$6.48B	$11.98B
Dividend Yield	N/A	1.70%	2.67%	5.58%
P/E Ratio	-2.40	17.68	23.68	23.74
Price / Sales	7.30	303.96	514.60	115.22
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	7.68	3.83	10.34	6.78
Net Income	-$22.39M	$75.85M	$3.57B	$337.51M
7 Day Performance	1.10%	-2.00%	0.24%	-2.34%
1 Month Performance	-9.64%	-5.85%	3.22%	1.88%
1 Year Performance	-36.49%	14.03%	22.20%	25.55%

Plus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSTV Plus Therapeutics	2.8355 of 5 stars	$5.53 +2.2%	$56.40 +919.9%	-32.0%	$37.24M	$5.21M	N/A	20	Analyst Forecast Gap Down
HYPR Hyperfine	3.0624 of 5 stars	$1.52 -2.6%	$1.78 +17.3%	+77.1%	$154.86M	$11.40M	N/A	190
CVRX CVRx	2.0205 of 5 stars	$5.43 -2.7%	$11.50 +111.8%	-17.7%	$148.07M	$56.65M	N/A	160	Gap Down
SNWV Sanuwave Health	1.6733 of 5 stars	$15.85 -3.8%	$51.00 +221.8%	-47.9%	$141.62M	$44.05M	48.03	40
MBOT Microbot Medical	2.1753 of 5 stars	$1.98 -2.5%	$7.50 +278.8%	-35.2%	$136.35M	N/A	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSTV) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Plus Therapeutics (PSTV) Competitors

PSTV vs. HYPR, CVRX, SNWV, MBOT, and NNOX

How does Plus Therapeutics compare to Hyperfine?

Summary

How does Plus Therapeutics compare to CVRx?

Summary

How does Plus Therapeutics compare to Sanuwave Health?

Summary

How does Plus Therapeutics compare to Microbot Medical?

Summary

How does Plus Therapeutics compare to Nano-X Imaging?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Plus Therapeutics (PSTV) Competitors

PSTV vs. HYPR, CVRX, SNWV, MBOT, and NNOX

How does Plus Therapeutics compare to Hyperfine?

Do analysts recommend PSTV or HYPR?

Does the media favor PSTV or HYPR?

Is PSTV or HYPR more profitable?

Do insiders & institutionals believe in PSTV or HYPR?

Which has more risk & volatility, PSTV or HYPR?

Which has better valuation & earnings, PSTV or HYPR?

Summary

How does Plus Therapeutics compare to CVRx?

Which has more volatility & risk, PSTV or CVRX?

Which has preferable valuation & earnings, PSTV or CVRX?

Do institutionals & insiders hold more shares of PSTV or CVRX?

Does the media favor PSTV or CVRX?

Is PSTV or CVRX more profitable?

Do analysts rate PSTV or CVRX?

Summary

How does Plus Therapeutics compare to Sanuwave Health?

Which has more risk & volatility, SNWV or PSTV?

Which has preferable valuation and earnings, SNWV or PSTV?

Do analysts rate SNWV or PSTV?

Does the media prefer SNWV or PSTV?

Do insiders and institutionals hold more shares of SNWV or PSTV?

Is SNWV or PSTV more profitable?

Summary

How does Plus Therapeutics compare to Microbot Medical?

Is PSTV or MBOT more profitable?

Which has more volatility and risk, PSTV or MBOT?

Do insiders & institutionals hold more shares of PSTV or MBOT?

Do analysts prefer PSTV or MBOT?

Which has better earnings and valuation, PSTV or MBOT?

Does the media favor PSTV or MBOT?

Summary

How does Plus Therapeutics compare to Nano-X Imaging?

Does the media favor PSTV or NNOX?

Is PSTV or NNOX more profitable?

Which has more risk & volatility, PSTV or NNOX?

Which has higher valuation and earnings, PSTV or NNOX?

Do institutionals and insiders hold more shares of PSTV or NNOX?

Do analysts prefer PSTV or NNOX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools